PAM
RNTX

PVG Asset Management’s Rein Therapeutics RNTX Stock Holding History

PVG Asset Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-5,880
Closed -$24.3K – 55
2022
Q3 		$24.3K Buy
+5,880
New +$24.8K 0.09% 35
2021
Q4 		$28.3K Buy
2,515
+1,337
+113% +$20.7K 0.1% 44
2021
Q3 		$24K Buy
1,178
+428
+57% +$9.38K 0.07% 39
2021
Q2 		$18.8K Buy
750
+32
+4% +$798 0.06% 52
2021
Q1 		$20.5K Buy
+718
New +$24.6K 0.07% 46

Other funds holding RNTX

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
KL
KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

PVG Asset Management's RNTX Position: Q4 2022 in Review

PVG Asset Management sold out of Rein Therapeutics (RNTX) in Q4 2022, closing a stake of 5,880 shares — an estimated $24.3K sold.

PVG Asset Management first reported a position in RNTX in Q1 2021 and held it in 5 quarters. The position peaked at $28.3K in Q4 2021. 19 funds tracked by Wall St. Rank hold RNTX as of Q4 2022.

  • PVG Asset Management reported no remaining Rein Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PVG Asset Management sold 5,880 Rein Therapeutics shares in Q4 2022, an estimated $24.3K.
  • PVG Asset Management first reported a position in Rein Therapeutics in Q1 2021 and held it in 5 quarters.
  • PVG Asset Management's Rein Therapeutics position peaked at $28.3K in Q4 2021.
  • 19 funds tracked by Wall St. Rank held Rein Therapeutics as of Q4 2022.

Based on PVG Asset Management's 13F filing for Q4 2022, filed 14 Feb 2023.